Ajanta Pharma Ltd - 532331 - Participation In Investor Conference
Ajanta Pharma has scheduled two analyst/institutional investor meetings. The first is with ICICI Securities India on May 29, 2026, and the second is with 360 ONE Capital on June 8, 2026, to discuss already published information.
May 19 2026 15:40:13
Ajanta Pharma Q4 net profit rises 18% despite ₹42 crore forex loss; revenue grows 21%
Ajanta Pharma reported robust Q4 FY24 results, with consolidated net profit increasing 66% to ₹203 crore and revenue from operations rising 20% to ₹1,054 crore, despite a ₹42 crore forex loss. The company's board also approved a share buyback of ₹351 crore at ₹2,770 per share, constituting 0.82% of the total paid-up equity share capital.
May 05 2026 23:57:33
Q4 Results LIVE Updates: Hero MotoCorp PAT ₹1,401 Cr, Coforge PAT ₹612 Cr beat estimates
The article provides live updates on Q4 FY26 earnings for numerous companies, with Ajanta Pharma among those scheduled to announce its financial results today, May 5, 2026. Detailed results for other companies such as United Breweries, Aeroflex Industries, and SRF have been released, but specific financial figures for Ajanta Pharma were not yet available in the provided updates.
May 05 2026 20:37:06
Ajanta Pharma Ltd - 532331 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Ajanta Pharma announced the upload of the audio recording of its earnings call, held on May 5, 2026, to its website. This allows investors to access the discussion regarding the company's financial performance.
May 05 2026 17:58:42
Q4 Results Live Updates: L&T earnings miss estimates; Shoppers Stop posts loss
Ajanta Pharma reported robust financial performance for Q4 FY26, with net profit increasing 18% year-on-year to ₹267 crore. The company's revenue also saw a significant rise of 21% to ₹1,422 crore during the same period.
May 05 2026 17:24:42
Ajanta Pharma Q4 net profit rises 18% despite ₹42 crore forex loss; revenue grows 21%
Ajanta Pharma reported its Q4 FY26 results with net profit rising 18% and revenue growing 21%, despite experiencing a ₹42 crore forex loss during the quarter.
May 05 2026 15:57:59
Ajanta Pharma Ltd - 532331 - Board Meeting Outcome for Outcome Of Board Meeting
Ajanta Pharma announced Q4 FY26 consolidated revenue increased 21% to ₹1,422 crore, with net profit up 18% to ₹267 crore. For the full year FY26, consolidated revenue was ₹5,453 crore and net profit reached ₹1,056 crore.
May 05 2026 15:25:54
Read More